Pediatrix Medical Group, Inc. (MD): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Pediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0000893949 false 0000893949 2026-07-21 2026-07-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21,
How this was made
The 30-second read
Why it matters
The disclosure updates management structure: Moore moves to an advisory role until Oct. 31, 2026, and David Haddock is appointed Executive Vice President, General Counsel, and Secretary.
Market read
Primarily governance and continuity information; no new financial or operational catalyst is provided.
What to watch
The key trading variable is whether the new GC role affects legal/regulatory posture; this filing does not disclose any pending investigations, settlements, or material legal developments.
Background
The company previously announced Mary Ann E. Moore would transition out of her EVP General Counsel and related roles before year-end; this 8-K formalizes the separation terms and successor appointment.
Ticker impact
Pediatrix Medical Group disclosed a separation agreement for EVP General Counsel Mary Ann E. Moore and appointed David Haddock as her successor.
Likely limited near-term impact unless investors view the departure as a governance risk; otherwise expect muted reaction.
The 8-K is an SEC primary filing detailing leadership changes and an advisory transition through Oct. 31, 2026, without new guidance, litigation, or material business terms.
Market effects
Minimal sector read-through; this is company-specific governance/leadership continuity.
None indicated.
None indicated.
Counterpoint
Investors may overreact to officer departures; the filing states the transition is termination without cause and includes an advisory period, which can reduce perceived disruption risk.
Key entities
- issuerPediatrix Medical Group, Inc.
Filed an 8-K describing the separation of EVP General Counsel Mary Ann E. Moore and appointment of David Haddock.
- executiveMary Ann E. Moore
Will serve in an advisory role until Oct. 31, 2026; transition is termination without cause under her employment agreement.
- executiveDavid Haddock
Appointed Executive Vice President, General Counsel, and Secretary of the company.
